ZeZentalis Pharma

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on the bottom line, with a GAAP EPS of -$0.59 vs. -$0.49 expected. The variance was driven primarily by a $7.0M one-time milestone payment to Recurium IP triggered by the ASPENOVA Phase 3 trial commencement. While R&D expenses rose 27.4% YoY to $35.2M, the company's cash runway was extended through late 2027 following a 40% workforce reduction in 2025. Management reaffirmed azenosertib's accelerated approval path for Cyclin E1-positive PROC, with topline DENALI data expected in H1 2027.